Follow the Coherus Oncology, Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.3bn. The latest transaction was reported on 9 June 2026 (Attribution). Among the most active insiders: Lanfear Dennis M. Every trade is free.
11
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Coherus Oncology, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
28Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
11,839 shares@ US$1.55100.0% of flowCommon StockSEC:0001610717-26-000016:0
11 of 11 declarations
Acerca de Coherus Oncology, Inc.
Coherus Oncology, Inc. es una empresa biofarmacéutica centrada en el desarrollo y la comercialización de terapias biosimilares para el tratamiento del cáncer. Cotiza en NASDAQ bajo el ticker CHRS.